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The Use of Pattern Differentiation in WHO-Registered Traditional Chinese 
Medicine Trials – a systematic review
ABSTRACT 
Introduction: Pattern differentiation is a critical component for traditional Chinese 
medicine (TCM) diagnosis and treatment. However, the issue of whether pattern 
differentiation is appropriately applied in TCM interventional trials, including Chinese 
herbal medicine (CHM) interventions and non-herbal TCM interventions, is unclear. 
The aim of this study was to i) systematically review the current status of pattern 
differentiation used in WHO-registered clinical trials for different types of TCM 
interventions; and ii) provide suggestions for improving the use of pattern 
differentiation in future clinical trial design.
Methods: The World Health Organization (WHO) International Clinical Trials Registry 
Platform (ICTRP) database was searched for all TCM interventional trials registered 
up to 31 December 2017. In this systematic review trials with a TCM pattern 
differentiation in their design were included. Descriptive statistics were collated to 
demonstrate the characteristics of pattern differentiation applied for different TCM 
interventional trials. 
Results: Among 2,955 TCM interventional trials registered during 1999-2017, 376 
(12.7%) trials included pattern differentiation. Of 376 trials, the use of pattern 
differentiation was identified in –title (30.6%), objective (50.5%), participants inclusion 
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(100%), outcomes (43.6%) and study background (12.5%). Further, 85.4% reported 
the specific name of the TCM intervention, 10.6% provided the intervention’s targeted 
pattern, 83.8% reported the specific name of the TCM pattern, 7.2% presented 
diagnostic criteria for the pattern studied, and 19.1% adopted a pattern-related 
outcome as primary outcome for evaluation.
Conclusion: The reporting and application of pattern differentiation in TCM trials were 
inadequate and confusing, which was mainly due to lack of clarity regarding study 
design, objectives, diagnostic criteria and outcomes.
Key words: Pattern differentiation; Clinical trial registration; Traditional Chinese 
medicine; Chinese medicine interventions; WHO registries; Systematic review
1. Introduction
Traditional Chinese medicine (TCM) is one of the oldest medical systems in the 
world, it is widely used in China and other East Asian countries, and increasingly 
throughout the rest of the world. It is perhaps the most widely practiced system of 
traditional east Asian medicine in many of those countries. It has long been thought 
to offer the possibility of offering an individualized approach to treatment [1]. The 
advent of personalized medicine with its tailored and individualized approach to 
diagnosis and treatment of disease may further demonstrate the importance, unique 
features and impact of pattern differentiation as applied in the clinical practice of TCM 
[2]. More recently, the WHO has released the new International Classification of 
Diseases (ICD-11), which includes new chapters, including one on traditional 
medicine conditions (e.g., This chapter refers to disorders and patterns which 
originated in ancient Chinese Medicine and are commonly used in China). Although 
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millions of people use traditional medicine worldwide, the diagnostic categories for 
traditional medicines have never been classified in this system [3]. Currently, TCM’s 
impact worldwide is increasing and there is a pressing need to further develop the 
unique aspects of its clinical practice [4]. There exists a variety of TCM interventions, 
such as Chinese herbal medicines (CHM), acupuncture, moxibustion, tuina 
(massage), cupping, guasha (scraping), Qigong, Tai Chi, etc.; however, the success 
in deciding on a TCM intervention depends on an accurate pattern diagnosis known 
as Bian-Zheng-Lun-Zhi (e.g. treatment based on pattern differentiation) [5]. According 
to TCM theory, a TCM pattern (also termed a syndrome or Zheng) is a pathological 
cluster or summary of signs and symptoms at a certain stage of a disease. Dependent 
on the pattern, the pattern may include the cause, pathological feature, properties and 
the relationship between the pathogens and the body’s resistance [6]. The patterns 
are named according to a cluster of associated signs and symptoms described in 
terms of yin, yang, exterior, interior, cold, heat, deficiency and excess, etc. A “pattern” 
(Zheng) is obtained through analyzing the “symptoms”, while the “disease” (Bing) 
comprises the whole morbid process and may include several different patterns [7]. 
Specifically, pattern differentiation refers to the analysis and summarization of the 
clinical symptoms obtained through the four diagnostic methods of TCM (inspection, 
auscultation and smell, inquiry, and pulse taking and palpation), after which TCM 
practitioners can accordingly determine the treatment based on the patient’s current 
essential pattern [8]. Accurate TCM pattern differentiation is critical and provides a 
diagnostic label as well as guiding the choice of TCM treatment using CHM and/or 
non-CHM interventions, utilizing the theory of correspondence between formula and 
pattern (e.g., Fang-Zheng-Dui-Ying) [9-10]. 
The reliable evidence to support how TCM treatment is based on pattern 
differentiation, usually depends on well-designed clinical trials, such as randomized 
controlled trials (RCTs) [11]. The first RCT using a TCM pattern differentiation design 
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was published in 1983 to examine the efficacy of CHM in primary liver cancer [12]. 
Since then, increasingly attention has been paid to the use of pattern differentiation in 
clinical trials [13-14]. Many TCM trials have preferred to adopt the model of integration 
of western medical (WM) disease and TCM pattern differentiation, for which the 
eligible participants are screened using both a WM disease criterion and TCM pattern 
diagnostic criterion [15-16]. TCM patterns have been used for many diseases in 
clinical trials, including irritable bowel syndrome [17], stroke [18], diabetic nephropathy 
[19], chronic obstructive pulmonary disease [20], and cancer [21]. Many scholars have 
suggested that patients with different diseases will benefit from TCM treatment 
according to pattern differentiation [22-23]. In practice, one disease may include 
several different TCM patterns, and conversely, different diseases may exhibit the 
same TCM pattern in the course of their development. Thus, the application of Bian-
Zheng-Lun-Zhi may “treat the same diseases with different methods”, or it may “treat 
different diseases with the same therapeutic method” [24]. Up to now, the debate on 
the standardization of patterns, such as diagnostic criteria, common patterns of a 
disease, etc. still continues [25]. Specific diagnostic criteria of the pattern or the 
identification of the patterns of specific diseases continue to develop [26-27], however, 
many studies still do not report the diagnostic criteria of a pattern, or present different 
pattern criteria of the same disease, so the results from different studies cannot be 
compared [28-29]. For different types of TCM interventional studies, the use of pattern 
differentiation varies. Compared to CHM (i.e. fixed or individualized CHM formulas), 
the lack of pattern differentiation in Chinese proprietary medicine (CPM), acupuncture, 
cupping or other non-CHM treatment is evident in many clinical trials [30-32]. Liu has 
pointed out that the evaluation of TCM clinical trials have mainly been conducted 
according to the efficacy assessment of TCM pattern differentiation (e.g. pattern-
related outcomes), although how to properly incorporate treatment based on pattern 
differentiation into a clinical trial remains complex [33]. 
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There are no data on how many clinical trials using TCM intervention protocols 
have been based on pattern differentiation. In addition, it is unclear whether Bian-
Zheng-Lun-Zhi has been rigorously applied across different types of intervention 
studies, as the theory of correspondence between formula and pattern is fundamental 
in correctly applying pattern differentiation [34]. For clinical research, the registration 
of a clinical trial is an important first step, and the study design of a trial should be 
reported at registration with a clear and transparent manner [35]. Given the 
importance of including the Bian-Zheng-Lun-Zhi in TCM trial design, the primary aim 
of this study was to examine TCM trials in WHO registries to identify specific features 
and common problems associated with the reporting of pattern differentiation design 
in trial registration records. A secondary aim was to provide suggestions for improving 
the quality of pattern differentiation design for future clinical trials.
2. Materials and methods
2.1. Data source
The database of the ICTRP (http://apps.who.int/trialsearch/) was searched on 15 
January 2018 for all TCM trials that had been registered up to 31 December 2017. 
There are 17 Registries in the ICTRP which include the Australian New Zealand 
Clinical Trials Registry (ANZCTR), Chinese Clinical Trial Register (ChiCTR), 
ClinicalTrials.gov, EU Clinical Trials Register (EU-CTR), International Standard 
Randomized Controlled Trial Number Register (ISRCTN), the Netherlands National 
Trial Register (NTR), Brazilian Clinical Trials Registry (ReBec), Clinical Trials 
Registry-India (CTRI), Clinical Research Information Service-Republic of Korea 
(CRiS), Cuban Public Registry of Clinical Trials (RPCEC), German Clinical Trials 
Register (DRKS), Iranian Registry of Clinical Trials (IRCT), Japan Primary Registries 
Network (JPRN), Pan African Clinical Trial Registry (PACTR), Sri Lanka Clinical Trials 
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Registry (SLCTR), Thai Clinical Trials Register (TCTR), and the Peruvian Clinical 
Trials Registry (REPEC). 
2.2. Search strategy
A standard Search, provided by WHO ICTRP (ICTRP Search Portal, 
http://apps.who.int/trialsearch/) was selected and the search strategy was undertaken 
using the terms ‘Chinese medicine OR traditional Chinese medicine OR Chinese 
materia medica OR Chinese herbal medicine OR acupuncture OR moxibustion OR 
tuina OR massage OR cupping OR guasha’, without any restrictions. 
2.3. Inclusion and exclusion criteria
Firstly, Firstly, this study focused on TCM clinical trials that registered up to 31 
December 2017, and did not examine other forms of traditional East Asian medicine 
such as those found in Japan, Korea, and thus does not reflect those systems. Thus, 
the following kinds of trials were excluded: Conventional Physical Therapy (CPT) or 
other Complementary Alternative Medicine (CAM) rather than TCM; 
Swedish/Thai/ice/aroma massage; Korean medicine which clearly identified that the 
theoretical basis of the trial did not utilize Chinese medicine theory as basis for the 
study. For example, trials with non-CHM interventions in Japanese/Korean were 
excluded because of clear indication of the use of specific Japanese massage therapy 
(e.g., Anma therapy) or Korean acupuncture medical (e.g., Sasang theory) as the 
basis in the registered information. 
Secondly, among the TCM trial registrations, TCM interventional studies were 
identified according to the information of ‘study type’ (e.g. interventional, observational, 
etc.) and the type of ‘intervention’ (e.g. CHM, acupuncture, cupping, etc.). Non-
interventional studies (e.g. observational studies, case studies, etc.) were excluded. 
The scope of TCM interventions included Chinese herbal medicines (e.g. single herb, 
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compound formula, Chinese proprietary medicines, etc.), acupuncture (electro- 
acupuncture, auricular acupuncture, etc.), moxibustion, tuina (massage), cupping, 
guasha (scraping), Qigong, etc.
Finally, after screening the full-text of the registered records, we included TCM 
intervention trials that had a diagnosis of pattern differentiation as participant inclusion 
criteria. There were no limitations in the comparisons and outcomes. Finally, we 
excluded TCM interventional studies without any pattern differentiation design. For 
example, although some trials reported the diagnostic criteria of disease studied 
according to both WM and TCM, there was no detailed information on TCM pattern 
differentiation in any of the registration information.
2.4. Data extraction and analyses
Using a predefined data extraction table, two authors (XZ and RT) extracted the 
data from each trial independently. Disagreements were resolved by consensus. If 
needed, a third author (CZ) was consulted. The content of the data extraction forms 
was comprised of two parts: I. Characteristics of pattern differentiation used in the trial 
(e.g. diseases and patterns studied, type of TCM intervention, study objective, study 
design, sample size of pattern differentiation group, and outcomes, etc.); and II. 
Assessment on whether the Bian-Zheng-Lun-Zhi was appropriately applied in the trial 
or not. This decision was based on seven questions (Box 1) related to the theory of 
correspondence between formula and pattern. Following this TCM theory could 
provide some guarantee that if the patients (or participants) have a specific TCM 
pattern, they will receive the correct matched treatment. All data were collected and 
tabled in Microsoft Office Excel (Version 2016). Categorical data is presented as 
number (n) and percent (%).
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Box 1. Seven questions on correspondence between formula and pattern
Q1: For TCM intervention(s), was a specific name(s) reported (e.g. not a generalized name of 
treatment determination on pattern differentiation)? 
Q2: For TCM intervention(s), was the definite applicable pattern(s) reported?
Q3: For TCM pattern(s) studied in a trial, was the specific name(s) reported?
Q4: For TCM pattern(s) studied in a trial, was the diagnostic criteria for each pattern reported?
Q5: For different patterns belonging to the same category of pattern classification (e.g. category of 
deficiency pattern includes Qi deficiency, Yang deficiency and Yin deficiency, etc.), was the same 
intervention entirely adopted, such as only one CHM studied in the trial?
Q6: For different patterns belonging to a different categories of pattern classification (e.g. deficiency 
of both Qi and Yin, deficiency of kidney Qi, stagnation of Qi and blood, etc), was the same 
intervention entirely adopted, such as only one CHM studied in the trial?
Q7: With reference to the above six answers, was the concept of correspondence between formula 
and pattern reflected in the study design?
3. Results
3.1. Search
The initial search identified 4,326 records. Preliminary screening excluded 987 
records due to them being non-TCM trials. After examination of the remaining 3,339 
TCM clinical trials, 2,955 interventional studies were chosen for further screening, 
which included 889 CHM trials and 2,066 non-CHM trials (Figure 1). Finally, a total of 
376 trials (12.7%, 376/2,955) were eligible for inclusion because they appeared to 
have information related to pattern differentiation in their design. Among them, 78.7% 
were CHM trials (n=296) and 21.3% were non-CHM trials (n=80). An ID list of all 
included records is provided in Supplementary 1 (S1).
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3.2. Distribution of years and registries
The 376 TCM intervention trials that included pattern differentiation design were 
registered between 2003 and 2017. The first clinical trial of TCM using pattern 
differentiation was registered in 2003, and the number of trial registrations showed a 
steady increase from 2013, then a further exponential increase during 2016-2017, 
which accounted for 52.1% (196/376) of the total numbers (Figure 2). Among the 17 
registries in the ICTRP, all the trials were identified in only 3 registries (17.6%, 3/17), 
including ChiCTR (332), ClinicalTrials.gov (41), and ISRCTN (3). The majority (88.3%, 
332/376) were registered in ChiCTR (i.e. China) (Figure 3). 
3.3. Descriptive characteristics of included trials 
As presented in Table 1, the included trials were classified as utilizing either WM 
and/or TCM (e.g., Bian Bing) diseases and TCM pattern (e.g., Bian Zheng) diagnostic 
criteria (99.2%, 373/376) or only single TCM pattern diagnostic criteria (0.8%, 3/376). 
The three most common body systems studied were diseases of the circulatory 
system (14.4%, 54/376), genitourinary system (13.0%, 49/376) and respiratory 
system (12.5%, 47/376). Various types of TCM interventions were utilized in the 376 
trials, of which CHM comprised the largest proportion (78.7%, 296/376), followed by 
acupuncture (8.2%, 31/376). However, 5.6% (21/376) of the included trials adopted 
more than one intervention (e.g. multiple interventions such as acupuncture plus 
moxibustion). For the CHM intervention, the most common design utilized a fixed 
standardized CHM formula (71.3%, 211/296), and the major dosage were granules 
(35.1%, 104/296). 
The most common study design was the RCT (97.9%, 368/376). Of 376 included 
trials, 367 (97.6%) trials had both a treatment group and a control group, of which 
most had a placebo control arm (29.4%, 108/367). This was followed by trials where 
a conventional drug (21.8%, 80/367) or an add-on design (17.7%, 65/367) was utilized. 
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For the treatment group that used pattern differentiation, the most common sample 
size utilized was 1-100 participants (67.8%, 255/376). 
3.4. Characteristics of pattern differentiation application in TCM interventional studies    
    As shown in Table 2, for included CHM trials, the use of pattern differentiation 
was reported in the study objective (55.7%, 165/296), outcomes (45.3%, 134/296), 
title (33.8%, 100/296) and study background (12.8%, 38/296). For non-CHM trials, the 
reporting rate of pattern differentiation were lower than those in CHM trials: outcomes 
(37.5%, 30/80), study objective (31.3%, 25/80), title (18.8%, 15/80) and study 
background (11.3%, 9/80). Of all included TCM trials, only 7.2% (27/376) provided a 
clearly defined diagnostic criteria basis or reference for the pattern differentiation. 
Furthermore, 43.6% (164/376) adopted pattern-related outcomes in the trial and 43.9% 
(72/164) of them were primary outcomes.
3.5. Assessment on pattern differentiation design in TCM interventional studies    
    Of 376 included trials, 14.6% (55/376) gave no specific name for the intervention, 
89.4% (336/376) did not report the applicable pattern scope of the intervention, 16.2% 
(61/376) gave no specific name for the pattern, while 92.8% (349/376) failed to 
provide the diagnostic criteria of the pattern. In addition, nearly 5% of the included 
trials adopted the same intervention (e.g.one intervention) to treat different types of 
TCM patterns, either in the same or different categories. This incomplete reporting led 
to uncertain judgement of most included trials (>90%) of whether the correspondence 
between formula and pattern were correctly applied in clinical trials. When comparing 
CHM trials with non-CHM trials, the reporting rate of patterns without a specific name 
was higher in non-CHM trials (33.8%) than in CHM trials (11.5%). Further details are 
provided in Table 3.
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4. Discussion
The concept of Bian-Zheng-Lun-Zhi (treatment based on pattern differentiation) 
is a fundamental and historically defined principle of TCM as well as offering guidance 
for the associated treatment. However, in this study, of 2,955 TCM intervention trials, 
only 12.7% (376/2,955) eligible trial registrations (namely TCM interventional trials 
with pattern differentiation design) were identified between 2003 and 2017, while the 
remaining 87.3% (2,579/2,955) trials were targeting diseases only. In addition, of the 
17 registries provided by WHO ICTRP, only 3 registries contained TCM intervention 
trial registrations that used pattern differentiation in their design. The largest number 
of the 376 included trials were registered with the Chinese registry, ChiCTR (88.3%, 
332/376), while the remaining trials were registered with the US registry (41 trials) and 
UK registry (3 trials), ClinicalTrials.gov and ISRCTN respectively. Of 2,955 TCM 
interventional trials, the number of non-CHM interventional trials (69.9%, 2,066/2,955) 
was much higher than that of CHM interventional trials (30.1%, 889/2,955). However, 
the use of pattern differentiation was more common in CHM interventional trials 
(78.7%, 296/376) than non-CHM interventional trials (21.3%, 80/376).  
Unfortunately, for most of the included trials it was difficult to confirm whether the 
study design of Bian-Zheng-Lun-Zhi was properly applied or not, due to the 
inadequate reporting of registered information. This included 14.6% which did not 
report the specific name of the TCM intervention, 89.4% which did not provide an 
applicable pattern scope of the intervention studied, 16.2% which did not report 
specific name of the TCM patterns and 92.8% which did not present diagnostic criteria 
of the pattern studied. Approximately 5% of the included trials adopted the same 
intervention (e.g. one intervention) to treat different types of TCM patterns (e.g. 
deficiency pattern and excess pattern). The key issue in the practice of using the Bian-
Zheng-Lun-Zhi is whether there was alignment/correspondence between the formula 
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and the pattern (“formula” included different types of TCM interventions in this study) 
[36-37]. This review, unfortunately, found that more than 90% of the included trials 
failed to reflect a correspondence between formula and pattern in their design. There 
were however some characteristics within the design and application of pattern 
differentiation in TCM clinical trials. These included (1) standardization of TCM pattern; 
(2) CHM interventions based on pattern differentiation; (3) non-herbal TCM 
interventions based on pattern differentiation; (4) group of pattern differentiation and 
its controls; (5) pattern-related outcome evaluation; and (6) usage of pattern 
differentiation in RCT.
4.1. Standardization of TCM pattern
    In this study, apart from the single TCM pattern design in 3 trials (0.8%, 3/376), 
most trials (99.2%, 373/376) included diagnosis of both disease and pattern in 
participant’s inclusion and exclusion criteria. However, only 27 trials (7.2%) clearly 
reported the diagnostic criteria of the TCM pattern. In reporting guidelines such as 
CONSORT extension for CHM formulas 2017 [38], it is important to choose patterns 
with well-recognized diagnosis criteria, and list the criteria in the trial publication, 
which is the same requirement as for trial registration [39]. Commencing from the 
1980's, more and more specific diagnostic criteria for TCM patterns and pattern of 
specific diseases have been developed [40-42], but the application of standardized 
pattern was limited. As a result, identifying patterns utilized in clinical trials is 
particularly challenging. Due to the different expression of pattern names (e.g. 
“insufficiency of the spleen and kidney” comparing with “deficiency of both qi and yang 
in spleen and kidney”) and/or the lack of specific diagnostic criteria provided in the 
trials, the results from different research could not be compared, even when the same 
pattern and/or same disease was studied. The issue of how to standardize the 
diagnostic procedure for TCM pattern differentiation research studies has been going 
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on for many years [43-44], and a variety of methods have been introduced and 
adopted by researchers [45-47]. The value of a standard diagnostic criteria ultimately 
depends on its use, which could be achieved by concerted efforts from registries, 
journal editors, and researchers and other interested parties.  
4.2. CHM interventions based on pattern differentiation
In this study, TCM pattern differentiation was primarily used in CHM interventional 
trials (n=296), of which the largest percentage was fixed CHM formulas (71.3%, 
211/296), followed by individualized CHM formulas (10.5%,31/296). It is generally 
considered that the usage of pattern differentiation with CPM is limited due to most 
being a non-prescription drug. Similarly, few trials (6.3%, 25/296) have used CPM 
based on pattern differentiation design. Some scholars have emphasized that the 
reasonable application of CPM must based on TCM pattern differentiation [48]. By 
contrast, some scholars have randomly investigated 7,233 CPM prescriptions in one 
hospital (Guangzhou) in 2012, and have found that 25.8% of CPM usage was not 
according to TCM pattern differentiation. The authors have explored the underlying 
reasons why this was the case such as: 1) the clinical medical staff, especially 
Western physicians had a lack of understanding of TCM theory; 2) the safety 
awareness of CPM application was poor; 3) the clinical application guiding some CPM 
instructions were ambiguous; and 4) there was no valid evaluation system for the 
clinical application of the CPM [49].
In terms of the reporting of the TCM pattern, the number of pattern differentiation 
reported in the title, study objective and study background of CHM trials were 100 
(33.8%), 165 (55.7%) and 38 (12.8%), respectively. The major problem in CHM 
treatment trials has been the focus on the inadequate reporting of information related 
to formula-pattern correspondences, including what is the applicable pattern scope of 
the CHM intervention treated in the trial? Other questions such as whether there is 
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consistency with the diagnostic criteria of pattern in participants inclusion, what is the 
principle of formula modified according to pattern, whether the application of CPM 
prescription must be based on TCM pattern differentiation and be consistent with 
publicly available references, etc., are also need to be addressed and reported if 
utilized within the study design. More than 90% of the included trials failed to provide 
these details in the registration records, so it is difficult to judge whether pattern 
differentiation is provided and appropriately used in clinical trials. 
4.3. Non-herbal TCM interventions based on pattern differentiation
For non-herbal TCM treatment trials, only 80 trials were identified which 
incorporated pattern differentiation design, including: acupuncture (31 trials), acupoint 
therapy (11 trials), moxibustion (9 trials), tuina/massage (6 trials), qigong (1 trial), TCM 
five element music therapy (1 trial), and multiple interventions of TCM (21 trials). 
Previous studies found that non-herbal TCM treatment trials, such as acupuncture 
trials, opted to choose a disease-oriented design and not include pattern 
differentiation [50-51]. So, whether pattern differentiation in non-herbal TCM 
treatments is necessary, and whether pattern differentiation can actually improve the 
efficacy of these kinds of interventions is still an unsolved but important question.
Compared to CHM trials, the percentage of reporting descriptions of TCM pattern 
were less evident in the title (18.8%, 15), study objective (31.3%, 25) and study 
background (11.3%, 9) of non-herbal TCM trials, especially in terms of the study 
objective compared to CHM trials. The problems apparent in CHM trials, such as the 
correspondence or alignment between treatment and pattern, were also more obvious 
in non-herbal TCM trials. In addition, more non-herbal TCM intervention trials did not 
report the specific name of the pattern (33.8%, 27) or intervention (16.3%, 13). For 
example, a description of “moxibustion for pattern differentiation” did not present the 
specific types of moxibustion and TCM pattern used in the trial. These numbers 
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indicated that little attention is paid to pattern differentiation in non-herbal TCM 
interventional trials. However, some studies have emphasized the importance and 
characteristics of non-herbal TCM treatment based on pattern differentiation [52-53]. 
For example, some scholars have pointed out that pattern differentiation of channels 
(e.g., Jing Luo Bian Zheng) is an important component in the acupuncture-
moxibustion pattern differentiation, especially when used for different kinds of jing-jin 
(e.g. channel sinews belonging to the jing-luo system) diseases and zang-fu diseases 
[54]. Therefore, high quality clinical trials that aim to investigate the relationship 
between efficacy and safety of non-herbal TCM treatments with and without pattern 
differentiation could be able to answer the above questions objectively. This study 
identified some trial registrations, and it is necessary to keep tracking and analyzing 
their results once published. 
4.4. Control Group design in TCM trials with pattern differentiation
    Of 376 included trials with pattern differentiation design groups, this study also 
identified 97.6% (367 trials) of them which included control group design. Regarding 
a control arm, 108 trials (29.4%) used a placebo, 80 trials (21.8%) chose conventional 
drugs, 65 trials (17.7%) adopted an add-on design, and 46 trials (12.5%) assigned 
other TCM interventions as a control (e.g. treatment with and without pattern 
differentiation, different dose or dosage form of the intervention, single TCM 
intervention and multiple TCM interventions, etc.). In addition, several trials selected 
more than one type of control group, e.g. combining conventional drug, placebo, 
and/or no treatment, etc. Among these different kinds of control groups, the use of a 
placebo control is increasing. A proper placebo should be identical to the real CHM 
intervention in physical form, sensory perception (visual, odor and taste), packaging, 
and labeling, and it should have no specific pharmaceutical activity [55-56].
The appropriate use and design of a control group is important for evaluating the 
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efficacy of a particular intervention based on pattern differentiation in a clinical trial. 
This is especially so when, the results of efficacy and safety of TCM treatment(s), with 
and without pattern differentiation, are important evidence for the value of pattern 
differentiation. Thus, researchers should select the appropriate type of control group 
according to the study objectives of TCM clinical trials with pattern differentiation [57]. 
Unfortunately, the reporting of pattern differentiation groups and the controls design 
was poor. For example, (1) 50% trials did not report pattern differentiation related 
information in the study objectives; (2) there was inadequate reporting of rationale 
and/or explanation for control design and; (3) no details of control groups were 
provided. Therefore, an adequate reporting of the control group is necessary for 
readers to understand the study design of pattern differentiation in the trial.
4.5. Pattern-related outcome evaluation
    In this study, 164 trials (43.6%) adopted TCM pattern-related outcomes, of which 
134 were CHM intervention trials and 30 were non-herbal TCM intervention trials. Of 
the 164 trials, 43.9% chose TCM pattern-related outcomes as the primary outcome 
for efficacy evaluation. Previous studies have shown that RCTs with pattern 
differentiation had a higher percentage of adopting pattern-related outcomes than 
those without pattern differentiation (P<0.01) [58]. The evaluation of pattern-related 
outcomes is the key indicator in the efficacy assessment of clinical trials using pattern 
differentiation design [59]. In general, pattern-related outcomes included TCM pattern 
scores, TCM symptom scale, tongue and pulse indicators, etc. However, in this study, 
most trials did not report the measurement methods and/or time points for 
administering the pattern-related outcomes, which indicated that there was a lack of 
consensus and standardization for TCM pattern scores for use in clinical trials. Some 
scholars have suggested that several statistical methods could be used to standardize 
the TCM pattern related outcome indicators, which aimed to include pattern outcomes 
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as a primary outcome in efficacy evaluation of a TCM clinical trial [60-61]. By contrast, 
some scholars have argued that TCM patterns cannot be used as outcome 
assessment in the clinical trial, for example, patients reported outcomes including 
TCM-related symptoms are better as outcomes assessments [62]. Further research 
into TCM pattern outcome evaluation is required to answer these questions.
4.6. Designing an RCT using pattern differentiation
Of the 376 included trials, 97.9% were RCTs, which indicated the wide use of 
TCM patterns in high quality evidence-based research. Recently, increasing numbers 
of TCM registered trials applying pattern differentiation occurred during 2016-2017 
(52.1%, 196/376). However, an argument against the use of pattern differentiation in 
an RCT is whether its own dynamic characteristic is applicable if stability requirements 
for disease and/or interventions is required [63]. Several questions relevant to this 
argument have not been well investigated, such as “How do the patterns and the 
nature of the disease change within individuals and among groups?”; “Are they 
synchronous?”; and “How do these changes affect the outcome assessment?”. 
Previous studies have suggested that the incorporation of pattern differentiation for 
further stratification of the patients could improve the efficacy of TCM interventions in 
clinical trials [64-65]. In contrast, other studies have pointed out that higher quality 
RCTs with pattern differentiation design are needed, which requires multidisciplinary 
collaborations amongst different professionals, researchers and scientists of both 
conventional medical and TCM practices with further input from experts from 
biomedical, bioinformatics, medical, pharmaceutical and TCM disciplines [66]. In 




This study has some limitations. Firstly, this review identified TCM intervention 
studies registered up to 31 December 2017. Any TCM clinical trials registered in 
regions which had not yet been included in WHO ICTRP by that cut-off period have 
not been included in this study. Secondly, this study mainly focused on collecting 
registration information from different registries rather than acquiring study protocols 
and publications for the specific details. Thirdly, some eligible TCM trials may well 
have been conducted without being registered. These limitations mean that the results 
of the study may not necessarily be comprehensive. We do however believe that the 
general trends indicated by the analysis of the information we did use, even if 
incomplete, are valid.
6. Recommendations
To improve the quality of pattern differentiation design in TCM clinical trials, we 
make the following recommendations:
(1) The design and application of pattern differentiation should depend on the 
research question. Researchers who include pattern differentiation in the design of 
their clinical trials should understand the rationale for the key factors related to the 
correspondence/alignment between the formula and the pattern, as discussed briefly 
in this review. 
(2) Commencing at trial registration, if the TCM interventions target a pattern-
oriented or a combination of disease-pattern orientation, it is recommended to report 
pattern differentiation in the title and study objective of a trial. If applicable, the 
rationale of the pattern differentiation design should be clearly enunciated. 
(3) Specific criteria of the pattern studied in the trial should be described 
adequately, including diagnostic criteria, inclusion and exclusion criteria. It is 
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recommended to choose the pattern with well-recognized criteria, especially for 
specific diseases. 
(4) Details of the TCM treatment, based on pattern differentiation, should be 
provided. For example, details regarding the intervention’s specific name, operational 
details and applicable treating pattern; the pattern’s specific name and diagnosis 
criteria should be reported. 
(5) Researchers should select the appropriate type of control group according to 
the study objective, study design and/or study phase.  
(6) The adoption of standardized pattern-related outcomes is suggested as 
primary outcome indicators for efficacy evaluation of TCM trials using a pattern 
differentiation design. 
7. Conclusion
    A total of 376 TCM interventional trial registrations were identified that included 
pattern differentiation in their design. Standards for pattern differentiation used in 
these included trials, especially in terms of specific criteria for participants, 
interventions, comparisons and outcomes, are lacking. The reporting quality of key 
information related to pattern differentiation, such as criteria of the pattern, needs to 
be improved in the future. It is recommended that if pattern differentiation is used, a 
trial should be appropriately designed according to the theories of 
correspondence/alignment between the formula (treatment) and the pattern.
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Figure legends
Figure 1. Flow chart of trials identified, included and excluded.
Figure 2. Number of included TCM trial registrations with pattern differentiation design from 2003 
to 2017.
Figure 3. Distribution of TCM registered trials with pattern differentiation design in 3 registries from 
2003 to 2017.





Table 1. Baseline characteristics of the included trials
Category Descriptive Characteristics N=376 (%)
Diagnostic criteria 1 Disease and pattern diagnosis 373 (99.2)
Single TCM pattern diagnosis 3 (0.8)
Diseases Diseases of the circulatory system 54 (14.4)
(ICD-11 codes) 2 Diseases of the genitourinary system 49 (13.0)
Diseases of the respiratory system 47 (12.5)
Diseases of the musculoskeletal system or connective tissue  41 (10.9)
Diseases of the digestive system 38 (10.1)
Certain infectious or parasitic diseases  28 (7.5)
Mental, behavioural or neurodevelopmental disorders  19 (5.1)
Neoplasms  18 (4.8)
Endocrine, nutritional or metabolic diseases 17 (4.5)
Diseases of the nervous system 14 (3.7)
Sleep-wake disorders 13 (3.5)
Diseases of the skin   8 (2.1)
Symptoms, signs or clinical findings, not elsewhere classified    7 (1.9)
Diseases of the immune system    6 (1.6)
Diseases of the blood or blood-forming organs 5 (1.3)
Certain conditions originating in the perinatal period 4 (1.1)
Pregnancy, childbirth or the puerperium  3 (0.8)
Traditional Medicine conditions - Module I  3 (0.8)
Diseases of the visual system    2 (0.5)
Types of interventions Chinese herbal medicine (CHM) 296 (78.7)
Acupuncture 31 (8.2)
Acupoint therapy 3 11 (2.9)
Moxibustion 9 (2.4)
Tuina (massage) 6 (1.6)
Qigong 1 (0.3)
TCM Five element music therapy 1 (0.3)
Multiple interventions 4 21 (5.6)
Types of CHM intervention5 Fixed CHM formulas 211 (71.3)
Individual CHM formulas 31 (10.5)
Chinese proprietary medicine (CPM)  25 (8.4)
Not reported  29 (9.8)
CHM dosage form 6 Granule 104 (35.1)
(The top three) Capsule 39 (13.2)
Decoction 22 (7.4)
Study design RCT 368 (97.9)
Others 7 8 (2.1)
Assignment Single arm   9 (2.4)
Treatment group vs control group 367 (97.6)
Study arms 8 TCM intervention vs placebo group 108 (29.4)
TCM interventions vs conventional drug 80 (21.8)
TCM intervention+conventional drug vs placebo/other TCM  65 (17.7)
intervention+conventional drug
TCM intervention vs other TCM intervention  46 (12.5)
TCM intervention+conventional drug vs conventional drug  22 (6.0)
TCM intervention vs conventional drug vs TCM 
intervention+conventional drug
 12 (3.3)
TCM intervention vs placebo vs other TCM intervention/no 
treatment
 11 (3.0)
TCM intervention vs conventional drug vs placebo  10 (2.7)
TCM intervention vs no treatment   5 (1.4)
TCM vs conventional drug vs other TCM intervention   4 (1.1)
TCM intervention +placebo vs other TCM intervention+placebo   2 (0.5)
TCM intervention+conventional drug vs other TCM 
intervention+conventional drug vs conventional drug
  1 (0.3)
TCM intervention vs other TCM intervention+placebo vs 
placebo
  1 (0.3)
Sample size of PD group 9 1-100  255 (67.8)
101-300 100 (26.6)
301-500   17 (4.5)
> 500    3 (0.8)
1 This column is according to the inclusion criteria of participants in each trial registration record. The disease and pattern diagnosis 
included WM disease and/or TCM disease (e.g., Bing) diagnosis plus TCM pattern (e.g., Zheng) diagnosis. The single TCM pattern 
diagnosis means there was no WM and/or TCM disease diagnosis.
2 According to International Statistical Classification of Diseases and Related Health Problems ICD-11 for Mortality and Morbidity 
Statistics (2018).
3 Acupoint therapy included acupressure, acupoint injection, catgut embedment in acupoint, and acupoint application. 
4 Multiple interventions refer to the combination of TCM therapies. For example, acupuncture and moxibustion, acupuncture and 
cupping, massage and cupping, CHM plus any TCM external treatment, etc.
5 6The percentage of these two columns (e.g. CHM types and dosage form) were based on the total number of CHM trials of 296, 
respectively.
7 Others refers to non-RCT trials, including cross-sectional, case-control study, case series, etc.
8 The trials included two groups assignment (n = 367) were used for the category of control group design. We calculated the 
percentage of each control group was based on the total number of 367. 
9 PD group refers to treatment group that used the TCM pattern differentiation.
Table 2. Characteristics of pattern differentiation application in the included trials 1






Title included PD 100 (33.8) 15 (18.8) 115 (30.6)
Study objective included PD 165 (55.7) 25 (31.3) 190 (50.5)
Study background included PD 38 (12.8) 9 (11.3) 47 (12.5)
Diagnostic criteria included PD 296 (100) 80 (100) 376 (100)
PD diagnosis with a clearly criteria 
basis or reference
21 (7.1) 6 (7.5) 27 (7.2)
Outcomes included PD-related 
indicator 3
134 (45.3) 30 (37.5) 164 (43.6)
PD-related outcome as primary 
outcome 4
56 (41.8) 16 (53.3) 72 (43.9)
1 To calculate the percentage of the term regarding “pattern differentiation (PD)” that reported in the following items of a trial: title, 
study objective, background, diagnosis and outcomes. For PD diagnosis, we added to calculate the percentage of those had a clearly 
reporting of diagnostic criteria basis or reference.
2 Trials with multiple interventions (n=21) were also calculated to the category of non-CHM trials, although some of them included a 
CHM intervention (n=12).
3 PD-related outcome(s) including TCM pattern score, TCM symptom score, Patterns (including clinical symptoms, signs, tongue, 
pulse), and the efficacy of TCM pattern, etc.
4 The percentage of this item was based on the number of PD-related outcomes, respectively. For example, 41.8%=56/134.
Table 3. Assessment on pattern differentiation design in the included trials






Q1 Gave no specific name of the intervention1 42 (14.2) 13 (16.3) 55 (14.6)
Q2 Fail to provide the applicable pattern scope of 
the intervention2
265 (89.5) 71 (88.8) 336 (89.4)
Q3 Gave no Specific name for the pattern 34 (11.5) 27 (33.8) 61 (16.2)
Q4 Fail to report the diagnostic criteria for the 
pattern (e.g. related standards or references)
275 (92.9) 74 (92.5) 349 (92.8)
Q5 Same intervention was used for different 
patterns in the same category
13 (4.4) 4 (5.0) 17 (4.5)
Q6 Same intervention was used for different 
patterns in the different categories
15 (5.1) 4 (5.0) 19 (5.1)
Q7 The concept of correspondence between 
formula (intervention) and pattern was unclarified in 
the trial design 3
291 (98.3) 76 (95.0) 367 (97.6)
1 For example, a specific name of the intervention included Ruan-Jian-San-Jie Capsule (a CHM Formula), 
Acupuncture of the five heart acupoints, etc. By contrast, a generalized name was classified to the answer that 
without a specific name, such as CHM granule, TCM treatments based on pattern differentiation, Chinese herbs, 
etc. These kinds of names are difficult to figure out what specific technologies and/or what specific compositions 
of CHM were adopted in a trial.
2 For example, a CHM intervention (Er-Zhi Wan that included herbs nourishing the Kidney-yin) adopted in a trial 
had reported its applicable pattern scope was the pattern of Kidney-yin deficiency. This kind of reporting was 
classified as “provide the applicable pattern scope of the intervention”. By contrast, a tuina intervention (Shanghai 
pediatric massage) adopted in a trial did not report its associated treating scope of the pattern, it was not possible 
to judge whether the intervention was applicable for excessive pattern or deficiency pattern. This kind of reporting 
was classified as “failed to provide the applicable pattern scope of the intervention”.
3 The assessment on Q7 was based on the answers of the previous Q1-Q6, especially in Q1-Q4. If the intervention 
and the pattern had reported their specific names, and they had correspondence between the treating scope of 
the intervention and the pattern studied with a related criterion. This kind of treatment based on pattern 
differentiation was classified as “clarified”. By contrast, if some of the reporting in Q1-Q6 were incomplete, the Q7 
was classified as “unclarified”.
S 1: Included trials ID
ChiCTR(n=332)
ChiCTR-IOR-17014195 ChiCTR-IOC-17013954 ChiCTR-IOC-17013974 ChiCTR-IOR-17013931
ChiCTR-IIR-17013983 ChiCTR-IOR-17013829 ChiCTR-IOR-17013791 ChiCTR-IOR-17013779
ChiCTR-IPR-17013758 ChiCTR-IOR-17013699 ChiCTR-INR-17013653 ChiCTR-IIR-17013609
ChiCTR-IOR-17013577 ChiCTR-IIR-17013532 ChiCTR-INR-17013495 ChiCTR-INR-17013467
ChiCTR-IOR-17013390 ChiCTR-IOR-17013387 ChiCTR-IOR-17013378 ChiCTR-IID-17013318
ChiCTR-IIR-17013275 ChiCTR-INR-17013222 ChiCTR-IOR-17013189 ChiCTR-INR-17013157
ChiCTR-INR-17013155 ChiCTR-IIR-17013018 ChiCTR-INR-17013012 ChiCTR-IPR-17012999
ChiCTR-IPR-17013000 ChiCTR-IOR-17012986 ChiCTR-IIR-17012977 ChiCTR-INR-17012938
ChiCTR-INC-17012872 ChiCTR-IOR-17012818 ChiCTR-IOR-17012811 ChiCTR-INR-17012803
ChiCTR-IOR-17012792 ChiCTR-IOR-17012693 ChiCTR-INR-17012674 ChiCTR-INR-17012670
ChiCTR-IOR-17012610 ChiCTR-IPR-17012500 ChiCTR-INR-17012490 ChiCTR-IOR-17012471
ChiCTR-IOR-17012468 ChiCTR-INR-17012452 ChiCTR-IOR-17012400 ChiCTR-IOR-17012287
ChiCTR-IIR-17012250 ChiCTR-IPR-17012151 ChiCTR-IOR-17012477 ChiCTR-IOR-17012111
ChiCTR-IOR-17012066 ChiCTR-IPR-17012014 ChiCTR-INR-17011949 ChiCTR-IIR-17011940
ChiCTR-INR-17011916 ChiCTR-IIR-17011831 ChiCTR-IOR-17011785 ChiCTR-INR-17011791
ChiCTR-IPR-17011699 ChiCTR-IPR-17011618 ChiCTR-IPR-17011555 ChiCTR-IPR-17011549
ChiCTR-IOR-17011518 ChiCTR-INR-17011491 ChiCTR-INR-17011493 ChiCTR-IOR-17011429
ChiCTR-IIR-17011407 ChiCTR-INR-17011284 ChiCTR-IPR-17011247 ChiCTR-INR-17011194
ChiCTR-INR-17011110 ChiCTR-IIR-17011106 ChiCTR-IOR-17011083 ChiCTR-IOR-17011067
ChiCTR-INR-17011062 ChiCTR-IPR-17011069 ChiCTR-INR-17011060 ChiCTR-INR-17011056
ChiCTR-INR-17011057 ChiCTR-INR-17011042 ChiCTR-IPR-17011035 ChiCTR-INR-17011023
ChiCTR-IOR-17011028 ChiCTR-IOR-17011036 ChiCTR-IOR-17011014 ChiCTR-IPR-17010970
ChiCTR-IPR-17010940 ChiCTR-IOR-17010910 ChiCTR-INR-17010801 ChiCTR-IPR-17010752
ChiCTR-IOR-17010748 ChiCTR-IOR-17010706 ChiCTR-INR-17010694 ChiCTR-INR-17010667
ChiCTR-IOR-17010580 ChiCTR-IOR-17010551 ChiCTR-INR-16009989 ChiCTR-IOR-17010516
ChiCTR-INR-17010502 ChiCTR-IOR-17010870 ChiCTR-INR-17010410 ChiCTR-IOR-17010397
ChiCTR-INR-17010324 ChiCTR-IOR-14005387 ChiCTR-IPR-14005341 ChiCTR-IPR-14005381
ChiCTR-TRC-13003519 ChiCTR-IOR-15005985 ChiCTR-ICR-15006657 ChiCTR-IIR-15007567
ChiCTR-IOR-14005744 ChiCTR-ICR-15006257 ChiCTR-IOR-15006313 ChiCTR-IOR-15005902
ChiCTR-IOR-15006149 ChiCTR-IPR-14005441 ChiCTR-IPR-14005665 ChiCTR-IPR-15006758
ChiCTR-IPR-15006759 ChiCTR-IOR-15006626 ChiCTR-IOR-15006812 ChiCTR-IPR-14005269
ChiCTR-IPR-14005357 ChiCTR-IPR-14005361 ChiCTR-IPR-15005760 ChiCTR-TRC-09000468
ChiCTR-TRC-09000565 ChiCTR-TRC-10000843 ChiCTR-TRC-10000957 ChiCTR-TRC-11001255
ChiCTR-TRC-08000204 ChiCTR-TRC-10001074 ChiCTR-TRC-10001518 ChiCTR-TRC-11001274
ChiCTR-TRC-12003062 ChiCTR-TRC-11001297 ChiCTR-TRC-12003871 ChiCTR-TRC-11001365
ChiCTR-TRC-13003086 ChiCTR-TRC-11001382 ChiCTR-TRC-11001755 ChiCTR-TRC-13003239
ChiCTR-TRC-13003303 ChiCTR-TRC-13003304 ChiCTR-TRC-13003324 ChiCTR-TRC-12001929
ChiCTR-TRC-13003326 ChiCTR-TRC-13003434 ChiCTR-TRC-12002367 ChiCTR-TRC-13003533
ChiCTR-TRC-12002402 ChiCTR-TRC-13003552 ChiCTR-TRC-13003668 ChiCTR-TRC-13003707
ChiCTR-TRC-13003742 ChiCTR-TRC-13003919 ChiCTR-TRC-13004029 ChiCTR-TRC-13004125
ChiCTR-TRC-13004412 ChiCTR-TRC-13003713 ChiCTR-TRC-13003793 ChiCTR-TRC-13003936
ChiCTR-TRC-13004038 ChiCTR-TRC-14004153 ChiCTR-TRC-14004171 ChiCTR-TRC-14004172
ChiCTR-TRC-14005099 ChiCTR-TRC-14004758 ChiCTR-TRC-14005135 ChiCTR-IOC-14005385
ChiCTR-IOR-14005404 ChiCTR-IOR-14005474 ChiCTR-IOR-14005510 ChiCTR-IOR-15005987
ChiCTR-IOR-15006515 ChiCTR-IPR-14005427 ChiCTR-IPR-15006194 ChiCTR-TRC-08000176
ChiCTR-TRC-09000352 ChiCTR-TRC-09000471 ChiCTR-TRC-10001016 ChiCTR-TRC-11001401
ChiCTR-TRC-12002330 ChiCTR-TRC-12002355 ChiCTR-TRC-12002524 ChiCTR-TRC-12002539
ChiCTR-TRC-12003063 ChiCTR-TRC-13003000 ChiCTR-TRC-13003203 ChiCTR-TRC-13003322
ChiCTR-TRC-13003323 ChiCTR-TRC-13003894 ChiCTR-TRC-13003985 ChiCTR-TRC-13004045
ChiCTR-TRC-13004085 ChiCTR-TRC-14004156 ChiCTR-TRC-14004179 ChiCTR-TRC-14005143
ChiCTR-TTRCC-13003732 ChiCTR-ICR-15006783 ChiCTR-IOR-14005372 ChiCTR-IOR-14005693
ChiCTR-IPR-15006344 ChiCTR-IPR-15006578 ChiCTR-IPR-15006630 ChiCTR-RPC-14005489
ChiCTR-TRC-07000037 ChiCTR-TRC-08000120 ChiCTR-TRC-08000166 ChiCTR-TRC-08000225
ChiCTR-TRC-09000311 ChiCTR-TRC-09000464 ChiCTR-TRC-09000533 ChiCTR-TRC-09000610
ChiCTR-TRC-10000808 ChiCTR-TRC-10000814 ChiCTR-TRC-10000845 ChiCTR-TRC-10001082
ChiCTR-TRC-10001105 ChiCTR-TRC-11001220 ChiCTR-TRC-11001511 ChiCTR-TRC-11001792
ChiCTR-TRC-12001923 ChiCTR-TRC-12001936 ChiCTR-TRC-12002054 ChiCTR-TRC-12002784
ChiCTR-TRC-12002846 ChiCTR-TRC-12002850 ChiCTR-TRC-12002857 ChiCTR-TRC-13003025
ChiCTR-TRC-13003242 ChiCTR-TRC-13003321 ChiCTR-TRC-13003337 ChiCTR-TRC-13003715
ChiCTR-TRC-13003893 ChiCTR-TRC-13003948 ChiCTR-TRC-13004026 ChiCTR-TRC-13004091
ChiCTR-IPR-16010154 ChiCTR-INR-16010063 ChiCTR-IOR-16010001 ChiCTR-INR-16009944
ChiCTR-INR-16009952 ChiCTR-INR-16009902 ChiCTR-IOR-16009905 ChiCTR-ION-16009815
ChiCTR-IOR-16009816 ChiCTR-IOR-16009797 ChiCTR-INR-16009783 ChiCTR-INR-16009764
ChiCTR-INR-16009746 ChiCTR-IOR-16009739 ChiCTR-INR-16009652 ChiCTR-INR-16009629
ChiCTR-INR-16009592 ChiCTR-ONN-16009534 ChiCTR-INR-16009557 ChiCTR-IOR-16009496
ChiCTR-INR-16009456 ChiCTR-IOR-16009410 ChiCTR-INR-16009404 ChiCTR-INR-16009401
ChiCTR-INR-16009363 ChiCTR-INR-16009328 ChiCTR-IIR-16009264 ChiCTR-INR-16009212
ChiCTR-IOR-16009210 ChiCTR-INR-16009821 ChiCTR-IOR-16007694 ChiCTR-IOR-16007697
ChiCTR-IOR-16008779 ChiCTR-IOR-16007795 ChiCTR-IIR-16008992 ChiCTR-IOR-16007693
ChiCTR-IOR-16007758 ChiCTR-IOR-16009045 ChiCTR-IIR-16008601 ChiCTR-IIR-16007751
ChiCTR-IOR-16008036 ChiCTR-IOR-16008394 ChiCTR-IOR-16008737 ChiCTR-INR-16008956
ChiCTR-IPR-16007835 ChiCTR-IPR-16009062 ChiCTR-IOR-16008082 ChiCTR-IPR-16008420
ChiCTR-IPR-16008973 ChiCTR-OPN-16008374 ChiCTR-INR-16007810 ChiCTR-INR-16007941
ChiCTR-INR-16009031 ChiCTR-ION-16008726 ChiCTR-IOR-16008323 ChiCTR-IOR-16008386
ChiCTR-IOR-16008557 ChiCTR-IOR-16008843 ChiCTR-IPR-16008108 ChiCTR-IPR-16009049
ChiCTR-IIR-16009020 ChiCTR-INR-16007766 ChiCTR-INR-16008136 ChiCTR-INR-16008879
ChiCTR-INR-16009028 ChiCTR-IOR-16008701 ChiCTR-IOR-16008947 ChiCTR-IPR-16007802
ChiCTR-IPR-16007809 ChiCTR-IPR-16008599 ChiCTR-IPR-16008775 ChiCTR-IPR-16009029
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ChiCTR-IPR-15006945 ChiCTR-IPR-15007208 ChiCTR-IPR-15007396 ChiCTR-IOR-15007545
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